Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR) price on Friday, December 23, rose 0.88% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.14.

A look at the stock’s price movement, the close in the last trading session was $1.13, moving within a range at $1.11 and $1.17. The beta value (5-Year monthly) was 1.62. Turning to its 52-week performance, $10.02 and $0.96 were the 52-week high and 52-week low respectively. Overall, EIGR moved -72.26% over the past month.

5 Undervalued Stocks For 2023

Approximately 544 miles north of Las Vegas lies what's been dubbed "the biggest lithium deposit in the US." One tiny company stands to be the biggest beneficiary because lithium "faces a long-term supply shortage," according to Barron's. This company, however, is sitting on a goldmine opportunity as it plans to produce 30,000 tonnes per annum over the next 3.5 years from this single deposit. Supplying the electric vehicle boom and potentially driving its stock price off the charts. But this is just one of the opportunities we have researched in our free report. The other four companies have just as much potential.

Click here to download your Free Copy…

Sponsored

Eiger BioPharmaceuticals Inc.’s market cap currently stands at around $57.91 million, with investors looking forward to this quarter’s earnings report slated for Mar 08, 2023 – Mar 13, 2023. Analysts project the company’s earnings per share (EPS) to be -$0.52, which has seen fiscal year 2022 EPS growth forecast to increase to -$2.14 and about -$0.79 for fiscal year 2023. Per the data, EPS growth is expected to be -114.00% for 2022 and 63.10% for the next financial year.

Analysts have a consensus estimate of $4.27 million for the company’s revenue for the quarter, with a low and high estimate of $3.78 million and $5.17 million respectively. The average forecast suggests up to a 40.50% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2022 to grow to $16.11 million, representing a 32.70% jump on that reported in the last financial year.

Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that EIGR is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.

5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 4 recommend EIGR as a Buy and 1 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.

EIGR’s current price about -55.81% and -70.68% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 20.37, while 7-day volatility ratio is 10.14% and 12.08% in the 30-day chart. Further, Eiger BioPharmaceuticals Inc. (EIGR) has a beta value of 1.57, and an average true range (ATR) of 0.28. Analysts have given the company’s stock an average 52-week price target of $9.20, forecast between a low of $3.00 and high of $20.00. Looking at the price targets, the low is -163.16% off current price level while to achieve the yearly target high, price needs to move -1654.39%. Nonetheless, investors will most likely welcome a -689.47% jump to $9.00 which is the analysts’ median price.

In the market, a comparison of Eiger BioPharmaceuticals Inc. (EIGR) and its peers suggest the former has performed considerably stronger. Data shows EIGR’s intraday price has changed 0.88% in last session and -78.57% over the past year. Comparatively, United Therapeutics Corporation (UTHR) has moved 0.57% on the day and only 30.27% in the past 12 months. Looking at another peer, we see that Avadel Pharmaceuticals plc (AVDL) price has dipped -3.19% on the day. However, the stock is -11.20% off its price a year ago. Moreover, Cytokinetics Incorporated (CYTK) is also down -3.84% in trading on the day while keeping a an uptrend of 3.57% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.59% and 0.53% respectively in the last trading.

If we refocus on Eiger BioPharmaceuticals Inc. (NASDAQ:EIGR), historical trading data shows that trading volumes averaged 1.64 million over the past 10 days and 801.33K over the past 3 months. The company’s latest data on shares outstanding shows there are 44.01 million shares.

The 5.25% of Eiger BioPharmaceuticals Inc.’s shares are in the hands of company insiders while institutional holders own 70.70% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.89 million on Oct 13, 2022, giving us a short ratio of 5.21. The data shows that as of Oct 13, 2022 short interest in Eiger BioPharmaceuticals Inc. (EIGR) stood at 4.29% of shares outstanding, with shares short rising to 1.7 million registered in Sep 14, 2022. Current price change has pushed the stock -78.03% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the EIGR stock continues to rise going into the next quarter.